Last updated 7 days ago
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
230 patients around the world
Available in Chile, Brazil, Argentina, United States
Bristol-Myers Squibb
17Research sites
230Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Hospital Británico de Buenos Aires - CABA
Recruiting
Instituto de Oncología Ángel H. Roffo - CABA, Buenos Aires
Recruiting
Instituto Oncológico de Córdoba IONC - Fundación Richardet Longo
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA
Recruiting
Instituto D'Or de Pesquisa e Ensino - Sao Paulo
Recruiting
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
Recruiting
StudyTRIDENT-3
SponsorBristol-Myers Squibb
Conditions
Non-small cell lung carcinomaLung cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06140836
